We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+18.95%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.85B
AUM Growth
-$38.7M
(-1.3%)
Cap. Flow
-$602M
Cap. Flow
% of AUM
-21.14%
Top 10 Holdings %
Top 10 Hldgs %
27.89%
Holding
132
New
16
Increased
23
Reduced
29
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$55.3M |
| 2 |
Xeris Biopharma Holdings
XERS
|
+$48.6M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$41.7M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$27.9M |
| 5 |
Tandem Diabetes Care
TNDM
|
+$27.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$93.4M |
| 2 |
DexCom
DXCM
|
+$41M |
| 3 |
DaVita
DVA
|
+$32.1M |
| 4 |
GSK
GSK
|
+$31.6M |
| 5 |
Viatris
VTRS
|
+$31.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 73.94% |
| 2 | Financials | 2.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MNK
1
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $130M | 4.58% |
6,988,248
-1,633,135
| -19% | -$26M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $109M | 3.84% |
6,609,894
| – | – |
|
3
Q32 Bio
QTTB
$255M
| $107M | 3.74% |
290,391
| – | – |
|
|
MRTX
4
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $64.1M | 2.25% |
1,300,365
+1,103,365
| +560% | +$41.7M |
|
|
5
Viatris
VTRS
$20.1B
| $63M | 2.21% |
1,742,111
-806,000
| -32% | -$31.6M |
|
|
MYOK
6
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $57.5M | 2.02% |
1,159,000
+90,320
| +8% | +$4.37M |
|
|
7
Tandem Diabetes Care
TNDM
$1.17B
| $56.7M | 1.99% |
2,573,305
+2,255,305
| +709% | +$27.7M |
|
|
DBVT
8
DBV Technologies
DBVT
$870M
| $55.9M | 1.96% |
290,000
| – | – |
|
9
Aclaris Therapeutics
ACRS
$793M
| $54.8M | 1.93% |
2,745,705
| – | – |
|
|
XLRN
10
DELISTED
Acceleron Pharma
XLRN
| $54.7M | 1.92% |
1,126,800
+511,800
| +83% | +$18.6M |
|
|
PTLA
11
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $54.6M | 1.92% |
+1,446,633
| New | +$55.3M |
|
|
12
Xeris Biopharma Holdings
XERS
$1.52B
| $47.4M | 1.67% |
+2,498,666
| New | +$48.6M |
|
13
Elevance Health
ELV
$80.9B
| $45.5M | 1.6% |
191,000
| – | – |
|
|
AET
14
DELISTED
Aetna Inc
AET
| $42M | 1.48% |
229,000
+64,000
| +39% | +$11.4M |
|
15
Editas Medicine
EDIT
$457M
| $41.5M | 1.46% |
1,158,841
| – | – |
|
|
BOLD
16
DELISTED
Audentes Therapeutics, Inc
BOLD
| $40.1M | 1.41% |
1,048,430
-336,040
| -24% | -$12.4M |
|
17
AnaptysBio
ANAB
$1.72B
| $40M | 1.4% |
562,989
-231,349
| -29% | -$19.4M |
|
18
Centene
CNC
$32.8B
| $40M | 1.4% |
649,072
-526,928
| -45% | -$30.4M |
|
|
19
Sarepta Therapeutics
SRPT
$1.82B
| $39.1M | 1.37% |
+296,000
| New | +$27.9M |
|
|
XENT
20
DELISTED
Intersect ENT, Inc
XENT
| $38.2M | 1.34% |
1,020,000
+187,500
| +23% | +$7.36M |
|
21
argenx
ARGX
$53.8B
| $37M | 1.3% |
447,029
+127,109
| +40% | +$11.4M |
|
22
CALL
CVS Health
CVS
$137B
| $36.5M | 1.28% |
566,800
| – | – |
|
|
23
CVS Health
CVS
$137B
| $35.4M | 1.24% |
550,000
| – | – |
|
24
BioCryst Pharmaceuticals
BCRX
$2.36B
| $34.7M | 1.22% |
6,063,496
-1,302,964
| -18% | -$7.17M |
|
|
SEM
25
DELISTED
Select Medical
SEM
| $33.7M | 1.18% |
3,448,448
| – | – |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q2 2018 Portfolio in Review
As of Q2 2018, Deerfield Management held 132 positions worth $2.85B, down 1.3% from $2.89B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Deerfield Management withdrew a net $602M in Q2 2018, closing 17 positions and reducing 29 holdings. Its most notable exit was AveXis, Inc. Common Stock, an estimated $93.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 75% a quarter earlier, followed by Financials.
Against the trend, Deerfield Management opened a new position in Portola Pharmaceuticals, Inc. worth $54.6M.
- Deerfield Management's largest Q2 2018 buy was Portola Pharmaceuticals, Inc.: 1,446,633 shares worth $54.6M.
- Deerfield Management added most to Mirati Therapeutics, Inc. Common Stock in Q2 2018, an estimated $41.7M increase.
- Deerfield Management's biggest Q2 2018 reduction was DexCom, cutting an estimated $41M.
- Deerfield Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $93.4M.
- Deerfield Management's ten largest holdings make up 28% of its $2.85B portfolio in Q2 2018.
- Deerfield Management opened 16 new positions and closed 17 in Q2 2018.
- Deerfield Management's portfolio value fell 1.3% quarter-over-quarter to $2.85B.
Based on Deerfield Management's 13F filing for Q2 2018, filed 14 Aug 2018.